Value Microcaps Zip Code Changers

[stock_peeker]

VVUS: Vivus Shares Jump 10% On Positive Obesity Drug Test Results (VVUS)
Sep 21, 2010 (SmarTrend News Watch via COMTEX) --
9/21/2010-Shares of Vivus (NASDAQ:VVUS) are trading over 10% higher Tuesday premarket after the company that develops and manufactures treatments for erectile dysfunction reported positive top-line results from a two-year study of its QNEXA controlled release capsules, which is an investigational therapy for the treatment of obesity.
The findings come from the SEQUEL study, a 108 weeks study including 675 obese patients.
Patients who took the top dose of QNEXA were able to get and maintain average weight loss through two years of 11.4% of their initial body weight, or 26 pounds.
The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia.